First, in respect to medical isotopes, we indicated several years ago that we would no longer be providing medical isotopes by 2016. We've alerted the world to that. In the meantime we have funded in a significant way alternative procedures that don't take the traditional approach, the traditional use of radiation. There are cyclotron approaches that have been proven scientifically and are now at the commercialization stage.
We funded three locations on the basis of a competitive process, academic and research groups that are in the process of making that a commercial determination. At this point we're cautiously optimistic that it can in fact be achieved, and this will be a significant improvement over the current process. Everything is moving as we hoped it would.